Karyopharm Therapeutics Inc - Asset Resilience Ratio

Latest as of June 2026: 9.10%

Karyopharm Therapeutics Inc (KPTI) has an Asset Resilience Ratio of 9.10% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Karyopharm Therapeutics Inc to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

$10.12 Million

Cash + Short-term Investments

Total Assets

$111.32 Million

All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2013–2025)

This chart shows how Karyopharm Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Karyopharm Therapeutics Inc asset portfolio.

Liquid Assets Composition Over Time

This chart breaks down Karyopharm Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Karyopharm Therapeutics Inc long-term investment intensity to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$10.12 Million	9.1%
Total Liquid Assets	$10.12 Million	9.10%

Asset Resilience Insights

Limited Liquidity: Karyopharm Therapeutics Inc maintains only 9.10% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Karyopharm Therapeutics Inc Industry Peers by Asset Resilience Ratio

Compare Karyopharm Therapeutics Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
ALK-Abelló A/S CO:ALK-B	Biotechnology	0.98%
Mirum Pharmaceuticals Inc NASDAQ:MIRM	Biotechnology	6.89%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
BB Biotech AG SW:BION	Biotechnology	92.97%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Wuhan Keqian Biology Co Ltd SHG:688526	Biotechnology	19.42%
Beijing Konruns Pharmaceutical Co Ltd SHG:603590	Biotechnology	10.55%

Annual Asset Resilience Ratio for Karyopharm Therapeutics Inc (2013–2025)

The table below shows the annual Asset Resilience Ratio data for Karyopharm Therapeutics Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	2.96%	$3.20 Million	$108.42 Million	-25.17pp
2024-12-31	28.12%	$46.24 Million	$164.42 Million	-29.78pp
2023-12-31	57.90%	$139.21 Million	$240.44 Million	+18.04pp
2022-12-31	39.86%	$142.78 Million	$358.17 Million	+27.37pp
2021-12-31	12.50%	$38.16 Million	$305.31 Million	-39.67pp
2020-12-31	52.17%	$163.32 Million	$313.05 Million	+7.05pp
2019-12-31	45.12%	$133.10 Million	$294.96 Million	-16.48pp
2018-12-31	61.60%	$210.18 Million	$341.19 Million	+18.63pp
2017-12-31	42.97%	$77.47 Million	$180.29 Million	-1.32pp
2016-12-31	44.29%	$79.89 Million	$180.38 Million	-10.15pp
2015-12-31	54.43%	$117.28 Million	$215.44 Million	+29.42pp
2014-12-31	25.01%	$55.12 Million	$220.34 Million	--
2013-12-31	0.00%	$0.00	$158.23 Million	--

pp = percentage points

About Karyopharm Therapeutics Inc

NASDAQ:KPTI USA Biotechnology

Market Cap

$40.57 Million

Market Cap Rank

#22781 Global

#5004 in USA

Share Price

$1.79

Change (1 day)

+5.29%

52-Week Range

$1.54 - $10.67

All Time High

$27.72